Hepatotoxicity with Thiazolidinediones

Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆

1999 • 3,339 citations

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

1998 • 1,728 citations

Drug-Induced Hepatotoxicity

2003 • 1,591 citations

Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors

1990 • 1,210 citations

Criteria of drug-induced liver disorders

1990 • 1,071 citations

Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

1996 • 1,004 citations

Prevalence of Type 2 Diabetes Mellitus among Persons with Hepatitis C Virus Infection in the United States

2000 • 689 citations

Association of diabetes mellitus and chronic hepatitis C virus infection

1999 • 675 citations

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

2000 • 630 citations

Update: Clinically Significant Cytochrome P‐450 Drug Interactions

1998 • 605 citations

Pathology of the liver

1979 • 586 citations

Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus

2000 • 547 citations

Nonalcoholic Steatohepatitis

1997 • 488 citations

Thiazolidinediones: a new class of antidiabetic drugs

1999 • 429 citations

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

2000 • 402 citations

A Pilot Study of A Thiazolidinedione, Troglitazone, in Nonalcoholic Steatohepatitis

2001 • 392 citations

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study

2000 • 374 citations

Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance

1998 • 373 citations

Liver pathology in morbidly obese patients with and without diabetes.

1990 • 312 citations

Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission

2000 • 302 citations

Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes

2000 • 301 citations

Drug-Induced Hepatotoxicity

1995 • 291 citations

Cholestatic Potential of Troglitazone as a Possible Factor Contributing to Troglitazone-Induced Hepatotoxicity: In Vivo and in Vitro Interaction at the Canalicular Bile Salt Export Pump (Bsep) in the Rat

2001 • 291 citations

Lessons from the glitazones: a story of drug development

2001 • 287 citations

Liver disease and diabetes mellitus.

2001 • 282 citations

Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

2000 • 265 citations

Drug-induced liver injury: Mechanisms and test systems

2001 • 261 citations

REVIEW: Nonalcoholic steatohepatitis

1997 • 254 citations

Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.

2000 • 248 citations

Causal or Casual?

1997 • 238 citations

Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone

1998 • 232 citations

Thiazolidinediones: an update

2000 • 230 citations

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1999 • 230 citations

Pioglitazone

2000 • 221 citations

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

2000 • 214 citations

Nonalcoholic Steatohepatitis

1999 • 213 citations

Hepatic Failure in a Patient Taking Rosiglitazone

2000 • 211 citations

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

2000 • 203 citations

Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report

1998 • 198 citations

Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report

2000 • 196 citations

Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.

2000 • 195 citations

Rosiglitazone

1999 • 188 citations

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study

1999 • 179 citations

Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s

1997 • 179 citations

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review

2000 • 178 citations

Clinical pharmacokinetics of pioglitazone

2000 • 161 citations

Thiazolidinediones and liver toxicity.

2001 • 157 citations

Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes.

1999 • 152 citations

THIAZOLIDINEDIONES

1997 • 148 citations

Liver Enzyme Monitoring in Patients Treated With Troglitazone

2001 • 146 citations

Oral Antidiabetic Agents

1998 • 132 citations

Drug-Induced Hepatotoxicity

1998 • 126 citations

Liver diseases and diabetes mellitus.

1970 • 121 citations

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus

2000 • 117 citations

Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group.

2000 • 115 citations

Diabetes Mellitus and the Liver

1985 • 114 citations

The role of hepatic peroxisome proliferator‐activated receptors (PPARs) in health and disease

2000 • 114 citations

Liver Function Tests in Diabetic Patients

1984 • 113 citations

Clinical Pharmacokinetics of Troglitazone

1999 • 113 citations

An Autopsy Case of Troglitazone-Induced Fulminant Hepatitis

1998 • 107 citations

Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs.

1997 • 98 citations

Troglitazone

1999 • 98 citations

Troglitazone Has a Scavenging Effect on Reactive Oxygen Species

1997 • 97 citations

Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes

2000 • 96 citations

Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes

2000 • 95 citations

Troglitazone

1997 • 89 citations

The pathology of diabetic hepatitis

1988 • 85 citations

Liver disturbances in obesity and diabetes mellitus.

1995 • 80 citations

Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.

1999 • 78 citations

Use of hepatocyte cultures for the study of hepatotoxic compounds

1997 • 77 citations

Insulin resistance and antidiabetic drugs

1999 • 73 citations

The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures.

2000 • 70 citations

Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents.

1999 • 66 citations

In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone

2000 • 62 citations

Mechanisms and clinical effects of thiazolidinediones

1997 • 59 citations

Antidiabetic Drugs Present and Future

2000 • 58 citations

Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes.

1999 • 57 citations

Drug-Induced Hepatic Disorders

1993 • 54 citations

Pioglitazone Hydrochloride Monotherapy Improves Glycemic Control in the Treatment of Patients With Type 2 Diabetes

2000 • 50 citations

The glitazones: proceed with caution

2000 • 44 citations

Troglitazone: Review and Assessment of Its Role in the Treatment of Patients with Impaired Glucose Tolerance and Diabetes Mellitus

1998 • 43 citations

Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination

2000 • 42 citations

Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data.

1997 • 41 citations

Safety and tolerability of pioglitazone

2000 • 39 citations

Troglitazone: an antidiabetic agent

1998 • 37 citations

Thiazolidinedione hepatotoxicity: a class effect?

2000 • 33 citations

Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency

1998 • 32 citations

Management of the Obese Diabetic Patient

2000 • 32 citations

Hepatic injury due to troglitazone.

2000 • 27 citations

Troglitazone. Is it all over?

1999 • 24 citations

Meta‐Analysis of Steady‐State Pharmacokinetics of Troglitazone and Its Metabolites

1997 • 23 citations

Troglitazone prevents fatty changes of the liver in obese diabetic rats

2000 • 23 citations

Severe but reversible hepatitis induced by troglitazone.

2000 • 21 citations

Pioglitazone: In vitro Effects on Rat Hepatoma Cells and in vivo Liver Hypertrophy in KKAv Mice

1997 • 20 citations

Diabetes drug withdrawn after reports of hepatic events

1997 • 19 citations

Drug Administration in Patients with Diabetes Mellitus

1998 • 18 citations

Learning to Use Troglitazone

1998 • 14 citations

Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials

2000 • 14 citations

Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG)

1999 • 14 citations

Metformin: a useful adjunct to insulin therapy?

2000 • 14 citations

Rosiglitazone.

2000 • 12 citations

Studies on the liver in diabetes mellitus. II. The significance of fatty metamorphosis and its correlation with insulin sensitivity.

1950 • 12 citations

Coadministration of Acetaminophen and Troglitazone: Pharmacokinetics and Safety

1998 • 9 citations

Rosiglitazone and pioglitazone: two new thiazolidinediones

2000 • 8 citations

New drug overview. Pioglitazone hydrochloride

2000 • 7 citations

Arzneimittelinteraktionen - ihre Bedeutung für eine sichere Therapie am Beispiel der neuen Wirkstoffgruppe der Thiazolidindione (Glitazone)

2011 • 6 citations

Factors Associated with the Risk of Liver Enzyme Elevation in Patients with Type 2 Diabetes Treated with a Thiazolidinedione

2001 • 6 citations

[Clinical effect and side effect of troglitazone].

2000 • 5 citations

Troglitazone-Associated Hepatic Failure

1999 • 4 citations

Troglitazone ban loses support

1999 • 3 citations

Effect of hepatic impairment on the pharmacokinetics of rosiglitazone

1999 • 3 citations

Not all glitazones tarnished by hepatotoxicity?

2000 • 1 citations

[Thiazolidinediones].

1999 • 1 citations

Deleted Work

1955 • 0 citations